Showing 281 - 300 results of 146,461 for search '(( 10 ((mg decrease) OR (a decrease)) ) OR ( 50 ((ns decrease) OR (we decrease)) ))', query time: 0.78s Refine Results
  1. 281

    Fig 3 - by Yan Shu (441370)

    Published 2022
    Subjects:
  2. 282

    Fig 4 - by Yan Shu (441370)

    Published 2022
    Subjects:
  3. 283

    Fig 2 - by Yan Shu (441370)

    Published 2022
    Subjects:
  4. 284
  5. 285

    Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis by Eric N. Ouattara (6890174)

    Published 2019
    “…In cost-effectiveness analysis, <i>Immediate ART</i> had a 10-year ICER of $680/YLS compared to <i>ART<350/μL</i>, ranging from cost-saving to an ICER of $1,440/YLS as transmission rates varied. …”
  6. 286
  7. 287
  8. 288
  9. 289

    Image_1_IL-12p40/IL-23p40 Blockade With Ustekinumab Decreases the Synovial Inflammatory Infiltrate Through Modulation of Multiple Signaling Pathways Including MAPK-ERK and Wnt.TIF by Renée H. Fiechter (10230473)

    Published 2021
    “…No serious adverse events occurred. We observed numerical decreases of all infiltrating cell subtypes at week 12, reaching statistical significance for CD68+ sublining macrophages. …”
  10. 290

    Design and Synthesis of Novel Spiro Derivatives as Potent and Reversible Monoacylglycerol Lipase (MAGL) Inhibitors: Bioisosteric Transformation from 3‑Oxo-3,4-dihydro‑2<i>H</i>‑ben... by Shuhei Ikeda (2380180)

    Published 2021
    “…Optimization of the left hand side afforded <b>4f</b> as a promising reversible MAGL inhibitor, which showed potent in vitro MAGL inhibitory activity (IC<sub>50</sub> 6.2 nM), good oral absorption, blood–brain barrier penetration, and significant pharmacodynamic changes (2-arachidonoylglycerol increase and arachidonic acid decrease) at 0.3–10 mg/kg, po. in mice.…”
  11. 291
  12. 292

    S10 Data - by Christoph Anders (4068499)

    Published 2024
    “…The study was conducted with 25%, 50%, and 75% of the upper body weight. Additionally, we varied the starting point (forward tilt and backward tilt) and the direction of rotation. …”
  13. 293

    Supplementary Material for: SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study by Schork A. (17795387)

    Published 2024
    “…Results: 42 patients (29 % with diabetic/hypertensive CKD, 31 % with IgA nephropathy; 88 % dapagliflozin 10 mg, 10 % dapagliflozin 5 mg, 2 % empagliflozin 20 mg; median eGFR 46 mL/min/1.73m² and albuminuria 1911 mg/g creatinine) participated in the study. …”
  14. 294

    Supplementary Material for: SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study by Schork A. (17795387)

    Published 2024
    “…Results: 42 patients (29 % with diabetic/hypertensive CKD, 31 % with IgA nephropathy; 88 % dapagliflozin 10 mg, 10 % dapagliflozin 5 mg, 2 % empagliflozin 20 mg; median eGFR 46 mL/min/1.73m² and albuminuria 1911 mg/g creatinine) participated in the study. …”
  15. 295
  16. 296
  17. 297

    Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant by Ittipat Meewan (7455041)

    Published 2019
    “…Several drugs targeting the protease have been developed, but drug-resistant mutant strains emerged. Here, we screened a library and synthesized a novel class of small molecules based on a tryptophan derivative scaffold identified as HCV NS3/4A protease inhibitors that are active against both wild type and mutant form of the protease. …”
  18. 298
  19. 299
  20. 300